Erratum: Safety and tolerability of levomilnacipran ER in major depressive disorder: Results from an open-label, 48-Week extension study(Clin Drug Investig (2013):33:761-771 DOI 10.1007/s40261-013-0126-5);Safety and tolerability of levomilnacipran ER in major depressive disorder: Results from an open-label, 48-week extension study

Clinical Drug Investigation

Volumn 33, Issue 10, 2013, Pages 761-771

  Mago, Rajnish ^a   Forero, Giovanna ^b   Greenberg, William M ^b   Gommoll, Carl ^b   Chen, Changzheng ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MILNACIPRAN; PLACEBO;

ANGINA PECTORIS; ARTICLE; BACKACHE; BODY WEIGHT; BRAIN DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; COLUMBIA SUICIDE SEVERITY RATING SCALE; CONSTIPATION; CONTROLLED STUDY; CONVULSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HEADACHE; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR DEPRESSION; MANIA; METABOLIC PARAMETERS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QT INTERVAL; RHINOPHARYNGITIS; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; T WAVE INVERSION; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TACHYCARDIA; TIME FACTORS;

EID: 84885110586     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0133-6     Document Type: Erratum

References (21)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
2. APA practice guideline for the treatment of patients with major depressive disorder, 3rd ed. Arlington: American Psychiatric Association; 2010. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1667485. Accessed 19 Aug 2013.
3. Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci. 2008;10(4):409-18.
4. Auclair AL, Martel JC, Assié MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338-47.
5. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732-47.
6. Blier P, Saint-Andre E, Hebert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007;10(1):41-50.
7. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657-65.
8. ® (levomilnacipran) extended-release capsules: U.S. Prescribing Information. St. Louis: Forest Pharmaceuticals, Inc.; 2013.
9. Chen L, Boinpally R, Gad N, et al. Drug-drug interactions of levomilnacipran sustained release capsule with ketoconazole, carbamazepine, or alprazolam in healthy subjects [poster]. 166th annual American Psychiatric Association Meeting; 2013 May 18-22; San Francisco.
10. Asnis G, Bose A, Gommoll C, et al. The efficacy and safety of levomilnacipran SR 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase III, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(3):242-8.
11. Bakish D, Gommoll C, Chen C, et al. Levomilnacipran ER 40 mg and 80 mg in major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study Int Clin Psychopharmacol. 2013 (in press).
12. Montgomery S, Mansuy L, Ruth A, et al. The efficacy and safety of levomilnacipran SR in major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2013;74(4):363-9.
13. Sambunaris A, Bose A, Gommoll C, et al. W14. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran SR in patients with major depressive disorder [abstract]. Neuropsychopharmacol. 2012;38(Suppl 1):S322-3.
14. Gommoll C, Bose A, Li H, et al. A randomized double-blind, placebo-controlled, flexible-dose study of levomilnacipran in patients with major depressive disorder [poster]. 24th Annual US Psychiatric and Mental Health Congress; 2011 Nov 7-10; Las Vegas.
15. Shiovitz T, Bose A, Greenberg WM, et al. The efficacy and safety of levomilnacipran SR in the prevention of relapse in major depressive disorder: results from a phase III clinical trial [poster]. 25th Annual US Psychiatric and Mental Health Congress; 2012 Nov 8-11; San Diego.
16. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. Text Rev. Washington, DC: American Psychiatric Association; 2000.
17. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
18. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-77.
19. Clinical Global Impressions. In: Guy W. ECDEU assessment manual for psychopharmacology. Rockville: National Institute of Mental Health; 1976, p. 218-222. DHEW publication no. 76-338.
20. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48(5):680-1689.
21. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-58.